drugset / Trial / NCT06548932
A Study to Evaluate the Safety, Tolerance, PK and PD Parameters of GZR33 and GZR101 in Healthy Male Adult Subjects
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a randomized, double-blind, placebo-controlled, single dose phase I clinical study. It is divided into two parts: part A , a single ascending dose assessment of GZR33, and partB, a single dose evaluation of GZR101.
Timeline
- Start
- 2022-06-30
- Primary completion
- 2023-02-24
- Completion
- 2023-02-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GZR101 | Unknown | — | Subcutaneous |
| Subject | GZR33 | Unknown | — | Subcutaneous |
Indications
No indication recorded.